financetom
Business
financetom
/
Business
/
Empire State Realty misses Q2 operating income estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Empire State Realty misses Q2 operating income estimates
Jul 23, 2025 1:45 PM

Overview

* Empire State Realty Trust ( ESRT ) Q2 net income per share at $0.04

* Core FFO per share for Q2 at $0.22

* Operating income missed analyst expectations, per LSEG data

* Co acquired Williamsburg retail asset for $31 mln

Outlook

* Company revises 2025 Core FFO guidance to $0.83-$0.86 per share

* Empire State Realty Trust ( ESRT ) expects year-end commercial occupancy of 89%-91%

* Company projects 2025 same-store cash NOI change of -2.0% to +1.5%

* Observatory NOI guidance lowered to $90M-$94M for 2025

Result Drivers

* HIGHER EXPENSES - Same-Store Property Cash NOI decreased 5.9% due to increased real estate taxes and property operating expenses

* POSITIVE LEASING SPREADS - Manhattan office leasing spreads increased by 12.1%, marking 16th consecutive qtr of positive spreads

* OBSERVATORY INCOME - Empire State Building Observatory generated NOI of $24.1 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $153.54

Rental mln

Revenue

Q2 Net $11.38

Income mln

Q2 Miss $35.12 $39.30

Operatin mln mln (3

g Income Analysts

)

Q2 $11.86

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the diversified reits peer group is "hold"

* Wall Street's median 12-month price target for Empire State Realty Trust Inc ( ESRT ) is $9.00, about 13.7% above its July 22 closing price of $7.77

* The stock recently traded at 92 times the next 12-month earnings vs. a P/E of 89 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ARMOUR Residential REIT Names Gordon Harper as Finance Chief
ARMOUR Residential REIT Names Gordon Harper as Finance Chief
Mar 14, 2024
03:46 AM EDT, 03/14/2024 (MT Newswires) -- ARMOUR Residential REIT ( ARR/PC ) said late Wednesday it has appointed Gordon Harper as chief financial officer, effective March 11, succeeding James Mountain. Harper will also remain as a controller of the company. Price: 19.93, Change: +0.1, Percent Change: +0.5 ...
Ichor Holdings Prices Stock Offering at $37.50 a Share
Ichor Holdings Prices Stock Offering at $37.50 a Share
Mar 14, 2024
03:47 AM EDT, 03/14/2024 (MT Newswires) -- Ichor Holdings ( ICHR ) said late Wednesday it priced an underwritten public offering of about 3.3 million ordinary shares at $37.50 per share. Underwriters have been granted a 30-day option to purchase up to 500,000 additional shares. Net proceeds will be used for debt repayments and for general corporate purposes, the company...
Exclusive-Chinese buyers cancel or postpone Australian wheat buys amid global oversupply
Exclusive-Chinese buyers cancel or postpone Australian wheat buys amid global oversupply
Mar 14, 2024
(Restores dropped 'to' in paragraph 2) By Naveen Thukral SINGAPORE (Reuters) -Chinese wheat importers have cancelled or postponed about one million metric tons of Australian wheat imports, trade sources with direct knowledge of the deals said, as growing world stockpiles drag down prices. The moves come after the U.S. government reported cancellation of more than 500,000 metric tons of U.S....
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
Mar 14, 2024
March 14 (Reuters) - Drugmaker AstraZeneca said on Thursday it would acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio. Amolyt, backed by investors including Danish drugmaker Novo Nordisk's parent firm Novo Holdings and EQT Life Sciences, is currently in the late-stage development of a therapy for hypoparathyroidism....
Copyright 2023-2026 - www.financetom.com All Rights Reserved